TY - T1的他汀类药物事件阿尔茨海默病,认知功能的改变,神经学和神经病理学JF -乔-神经病学SP - 2019 LP - 2020做wnl.0000342450.63664 10.1212/01.。首页f5六世- 71 - 24 AU -哈迪Meeran Hussain AU -名Zakria AU -阿卜杜勒·拉赫曼艾尔沙德Y1 2008/12/09 UR - //www.ez-admanager.com/content/71/24首页/2019.abstract N2 Arvanitakis et al.1检查929例来自宗教研究探讨他汀类药物是否修改订单病理学与阿尔茨海默病(AD)。大量的病人是必要的,以确定药物对疾病的影响参数。通常,一小部分患者服用药物,只有一小部分患者表现出感兴趣的特定的表型。这项研究开始于929名患者的119人正为他汀类药物使用。使用降脂药物治疗可能是通过自我报告,也没有时间的描述或药物的剂量。作者使用这些案件检查事件的广告,然后检查对病理学的影响。只有199年或231年的989例病例中有淀粉样蛋白或混乱病理学、分别;16.6%的这些情况下使用他汀类药物,这对应于33或38例淀粉样蛋白或混乱病理学。大概只有约三分之一(10 - 12例)用大脑渗透辛伐他汀等他汀类药物。 Obtaining statistical significance with such small numbers is difficult. Regardless of the considerations of number or power, we are struck by the absence of any effect associated with the statins. There was no overall effect for any measure. In addition, the authors stratified the results by type of medication: lipophilic statin, lipophobic statin, or nonstatin agent as well as by ApoE genotype. These stratifications could be important because other groups have observed more significant effects in ApoE4 subjects.2,3 The absence of any effect is striking and contrasts with the Cache County cohort in which Li et al. observed that subjects taking statins showed a significant reduction in neurofibrillary plaque formation, but no change in neuritic plaque formation.4 Moreover, Arvanitakis et al. did not examine inflammatory markers, which are known to decrease in subjects taking statins.5 The discrepancy between the … ER -